Emmaus Life Sciences, Inc.
EMMA
$0.016
$0.00053.23%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -39.91% | 1.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -39.91% | 1.88% | |||
| Cost of Revenue | -21.57% | 63.49% | |||
| Gross Profit | -41.33% | -1.01% | |||
| SG&A Expenses | -17.34% | -5.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.35% | -2.88% | |||
| Operating Income | -167.84% | 41.07% | |||
| Income Before Tax | -195.40% | 184.81% | |||
| Income Tax Expenses | 700.00% | -103.23% | |||
| Earnings from Continuing Operations | -195.68% | 183.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -195.68% | 183.65% | |||
| EBIT | -167.84% | 41.07% | |||
| EBITDA | -166.83% | 40.48% | |||
| EPS Basic | -195.80% | 182.90% | |||
| Normalized Basic EPS | -194.97% | 212.58% | |||
| EPS Diluted | -385.71% | 132.46% | |||
| Normalized Diluted EPS | -342.86% | 144.03% | |||
| Average Basic Shares Outstanding | 0.00% | 0.81% | |||
| Average Diluted Shares Outstanding | -60.75% | 156.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||